WO1997018855A1 - Dispositif pour ameliorer l'administration a l'organisme de substances et de composes biologiquement actifs - Google Patents

Dispositif pour ameliorer l'administration a l'organisme de substances et de composes biologiquement actifs Download PDF

Info

Publication number
WO1997018855A1
WO1997018855A1 PCT/EP1996/005086 EP9605086W WO9718855A1 WO 1997018855 A1 WO1997018855 A1 WO 1997018855A1 EP 9605086 W EP9605086 W EP 9605086W WO 9718855 A1 WO9718855 A1 WO 9718855A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
compound
electrode
substance
interest
Prior art date
Application number
PCT/EP1996/005086
Other languages
English (en)
Inventor
Eduard Naumovich Lerner
Leonid Lerner
Original Assignee
Eduard Naumovich Lerner
Leonid Lerner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eduard Naumovich Lerner, Leonid Lerner filed Critical Eduard Naumovich Lerner
Priority to JP9519384A priority Critical patent/JP2000500999A/ja
Priority to US09/077,123 priority patent/US6678553B2/en
Priority to AU76932/96A priority patent/AU7693296A/en
Priority to EP96939840A priority patent/EP0869829A1/fr
Publication of WO1997018855A1 publication Critical patent/WO1997018855A1/fr
Priority to US09/197,133 priority patent/US6410046B1/en
Priority to US10/051,817 priority patent/US7033598B2/en
Priority to US10/050,183 priority patent/US6913763B2/en
Priority to US10/393,254 priority patent/US7200432B2/en
Priority to US10/687,816 priority patent/US7593770B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode

Definitions

  • the degree of dissolution and subsequent ionization can be improved and regulated by means of the addition of suitable electrolytes forming buffer systems in the selected polar solvent or mixtures thereof .
  • Absorption is usually more rapid and more predictable than when a drug is given by mouth.
  • parenteral administration is particularly serviceable. If a patient is unconscious, uncooperative, or unable to retain anything given by mouth, parenteral therapy may become a necessity.
  • the injection of drugs also has its disadvantages. Strict asepsis must be maintained to avoid infection, an intravascular injection may occur when it is not intended, pain may accompany the injection, and it is often difficult for a patient to perform the injection himself if self-medication is a necessary procedure. Parenteral therapy is also more expensive and less safe than oral medication. Oral Ingestion. The rate of absorption of drugs from the gastrointestinal tract is generally proportional to the lipid solubility of the compound in question.
  • the hymen is a delicate incomplete membrane guarding the entrance to the vagina prior to maturity and sexual experience. It has one or more apertures to allow the outflow of menstrual blood and, according to their number and shape, is described as being annular, crescentic, septate or cribriform. If no other way for the introduction of medication is possible and it has to be done more than once, then an incision has to be made in the hymen so that electrodes can be easily introduced into the vagina.
  • the container matrix can be cross-linked with the drug components in place such as a silastic matrix, or the polymers can be prefabricated and sorbed with the components from solutions, for example with sponges or pads made of cellulose or woven fibre.
  • the container may also consist of a gel matrix structure, or be of a classical reservoir type holding a liquid.
  • the polymers can be either of linear or cross-linked type.
  • the container may be a polymeric matrix structure formed by mixing the selected drug, solvent, electrolyte, or other component (s) with an inert polymer by means of melt blending, solvent casting, compression or extrusion.
  • the delivery of said active compound is enhanced transnasally to the CNS from the nostril by passing the BBB by using a current intensity of up to 10 mA between an active electrode introduced into at least one nostril, and a passive electrode fixed on the back of the head or another place of the head.
  • the column was a Spherisorb 50DS
  • Braintissue Two ml of distilled water was added to 1 gram of brain tissue. The mixture was homogenized in an ultratorax apparatus (Ystral, Dottingen, Germany) at 10,000 rpm during 30 seconds. The homogenate was centrifuged at 3000 g during 5 min and further treated like plasma.
  • Fig. 2 shows the results obtained with rabbit Nr. 1 graphically.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Electrotherapy Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un dispositif pour améliorer l'administration d'un médicament ou de toute autre substance souhaitée à un organe ou tissu choisi, comprenant des électrodes spéciales, une de ces électrodes portant un récipient avec le médicament choisi ou une autre substance souhaitée, ces électrodes pouvant être placées à des emplacements prédéterminés de l'organe ou du tissu en question. Ces électrodes sont toutes connectées à une source d'énergie sélectionnée qui produit et entretient un champ d'énergie avant et durant l'administration accrue de cette substance et qui assure le transport de la substance dans la direction depuis l'électrode active vers l'électrode passive et dans l'organe ou le tissu. La source d'énergie peut être choisie de toute manière appropriée et elle peut émettre un champ électrique, un champ magnétique, des ondes ultrasoniques, des ondes haute énergie, telles que des faisceaux laser ou une combinaison de ceux-ci. En outre, l'invention concerne un procédé pour une administration accrue d'un médicament ou d'une autre substance souhaitée vers un organe ou un tissu interne cible d'un organisme, par exemple le cerveau, en court-circuitant la barrière hémato-encéphalique.
PCT/EP1996/005086 1995-11-21 1996-11-19 Dispositif pour ameliorer l'administration a l'organisme de substances et de composes biologiquement actifs WO1997018855A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP9519384A JP2000500999A (ja) 1995-11-21 1996-11-19 生体に対する生物学的活性物質および化合物の増進放出用デバイス
US09/077,123 US6678553B2 (en) 1995-11-21 1996-11-19 Device for enhanced delivery of biologically active substances and compounds in an organism
AU76932/96A AU7693296A (en) 1995-11-21 1996-11-19 Device for enhanced delivery of biologically active substances and compounds in an organism
EP96939840A EP0869829A1 (fr) 1995-11-21 1996-11-19 Dispositif pour ameliorer l'administration a l'organisme de substances et de composes biologiquement actifs
US09/197,133 US6410046B1 (en) 1996-11-19 1998-11-20 Administering pharmaceuticals to the mammalian central nervous system
US10/051,817 US7033598B2 (en) 1996-11-19 2002-01-18 Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US10/050,183 US6913763B2 (en) 1996-11-19 2002-01-18 Method and device for enhanced delivery of a biologically active agent through the spinal spaces into the central nervous system of a mammal
US10/393,254 US7200432B2 (en) 1995-11-21 2003-03-21 Device for enhanced delivery of biologically active substances and compounds in an organism
US10/687,816 US7593770B2 (en) 1996-11-19 2003-10-20 Method and device for enhanced delivery of a biologically active agent through the spinal spaces into the central nervous system of a mammal

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP95203173.0 1995-11-21
EP95203173 1995-11-21
EP95203601 1995-12-22
EP95203601.0 1995-12-22
EP96200082.4 1996-01-22
EP96200081 1996-01-22
EP96200081.6 1996-01-22

Related Child Applications (7)

Application Number Title Priority Date Filing Date
US09077123 A-371-Of-International 1996-11-19
US09/077,123 A-371-Of-International US6678553B2 (en) 1995-11-21 1996-11-19 Device for enhanced delivery of biologically active substances and compounds in an organism
US09/077,123 Continuation US6678553B2 (en) 1995-11-21 1996-11-19 Device for enhanced delivery of biologically active substances and compounds in an organism
US09/077,123 Continuation-In-Part US6678553B2 (en) 1995-11-21 1996-11-19 Device for enhanced delivery of biologically active substances and compounds in an organism
US09/197,133 Continuation US6410046B1 (en) 1996-11-19 1998-11-20 Administering pharmaceuticals to the mammalian central nervous system
US09/197,133 Continuation-In-Part US6410046B1 (en) 1996-11-19 1998-11-20 Administering pharmaceuticals to the mammalian central nervous system
US10/393,254 Division US7200432B2 (en) 1995-11-21 2003-03-21 Device for enhanced delivery of biologically active substances and compounds in an organism

Publications (1)

Publication Number Publication Date
WO1997018855A1 true WO1997018855A1 (fr) 1997-05-29

Family

ID=27236764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/005086 WO1997018855A1 (fr) 1995-11-21 1996-11-19 Dispositif pour ameliorer l'administration a l'organisme de substances et de composes biologiquement actifs

Country Status (1)

Country Link
WO (1) WO1997018855A1 (fr)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2323791A (en) * 1997-04-01 1998-10-07 Johann Zimmermann Electromagnetic pen for skin treatment
EP1011698A1 (fr) * 1997-09-09 2000-06-28 The University Of Western Australia Supplement osseux chimique
JP2002511385A (ja) * 1997-12-03 2002-04-16 ニューララブ リミテッド アルツハイマー病におけるβ−アミロイド関連変化を抑制する方法
GB2374018A (en) * 2000-11-17 2002-10-09 Gendel Ltd Ultrasound therapy
WO2003087368A3 (fr) * 2002-04-18 2004-04-29 Lynkeus Bio Tech Gmbh Moyens et procedes pour la modulation specifique de genes cibles dans le snc et l'oeil, et procedes pour leur identification
US6821274B2 (en) 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
US7033598B2 (en) * 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
ES2267333A1 (es) * 2004-01-27 2007-03-01 Universidad De Sevilla Dispositivo para la administracion de sustancias, estimulacion y registro "daser".
US7252655B2 (en) 1999-05-25 2007-08-07 Iomed, Inc. Ocular iontophoretic apparatus handle
US7481781B2 (en) 2000-11-17 2009-01-27 Gendel Limited Ultrasound therapy
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7799337B2 (en) * 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8034348B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
US8267851B1 (en) 2009-06-16 2012-09-18 James M Kroll Method and apparatus for electrically generating signal for inducing lucid dreaming
US8470792B2 (en) 2008-12-04 2013-06-25 Opko Pharmaceuticals, Llc. Compositions and methods for selective inhibition of VEGF
US8541384B2 (en) 2002-07-24 2013-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiogenesis
WO2013157937A1 (fr) * 2012-04-16 2013-10-24 Lerner Eduard N Dispositif d'administration intercérébrale améliorée de multiples substances biologiquement actives
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8954149B2 (en) 2004-02-20 2015-02-10 Brainsgate Ltd. External stimulation of the SPG
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation
US9044542B2 (en) 2007-12-21 2015-06-02 Carticept Medical, Inc. Imaging-guided anesthesia injection systems and methods
US9051363B2 (en) 1997-12-02 2015-06-09 Janssen Sciences Ireland Uc Humanized antibodies that recognize beta amyloid peptide
US9067015B2 (en) 2007-12-21 2015-06-30 Carticept Medical, Inc. System for injecting fluids in a subject
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US9398894B2 (en) 2007-12-21 2016-07-26 Carticept Medical, Inc. Removable cassette for articular injection system
US9644025B2 (en) 2007-10-17 2017-05-09 Wyeth Llc Immunotherapy regimes dependent on ApoE status
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR328311A (fr) * 1903-01-06 1903-07-09 J J Stanger Appareil électrique hygiénique
US3122137A (en) * 1961-10-30 1964-02-25 Erlanger Gustav Device for facilitating iontophoresis treatment of eyes
US3831598A (en) * 1972-09-28 1974-08-27 I Tice Sterile anesthetic instruments
SU992075A1 (ru) * 1981-02-04 1983-01-30 Львовский Научно-Исследовательский Институт Туберкулеза Устройство дл электрофореза лекарственных веществ
EP0378132A2 (fr) * 1989-01-09 1990-07-18 S.L. Cit Ionofor Dispositif d'administration de médicaments par ionophorèse pour un traitement local ou régional
WO1991016945A1 (fr) * 1990-05-07 1991-11-14 Feiring Andrew J Appareil et procede induisant la penetration d'un medicament dans des tissus internes
EP0470338A1 (fr) * 1990-07-24 1992-02-12 Empi, Inc. Electrode pour iontophorèse avec un réservoir et un site d'injection
EP0498353A2 (fr) * 1991-02-08 1992-08-12 Becton, Dickinson and Company Dispositif et méthode pour renouveler les électrodes en cours d'ionophorése
US5169384A (en) * 1991-08-16 1992-12-08 Bosniak Stephen L Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue
WO1994005361A1 (fr) * 1992-08-28 1994-03-17 Cortrak Medical, Inc. Appareil a matrice polymere d'administration de medicament et procede
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR328311A (fr) * 1903-01-06 1903-07-09 J J Stanger Appareil électrique hygiénique
US3122137A (en) * 1961-10-30 1964-02-25 Erlanger Gustav Device for facilitating iontophoresis treatment of eyes
US3831598A (en) * 1972-09-28 1974-08-27 I Tice Sterile anesthetic instruments
SU992075A1 (ru) * 1981-02-04 1983-01-30 Львовский Научно-Исследовательский Институт Туберкулеза Устройство дл электрофореза лекарственных веществ
EP0378132A2 (fr) * 1989-01-09 1990-07-18 S.L. Cit Ionofor Dispositif d'administration de médicaments par ionophorèse pour un traitement local ou régional
WO1991016945A1 (fr) * 1990-05-07 1991-11-14 Feiring Andrew J Appareil et procede induisant la penetration d'un medicament dans des tissus internes
EP0470338A1 (fr) * 1990-07-24 1992-02-12 Empi, Inc. Electrode pour iontophorèse avec un réservoir et un site d'injection
EP0498353A2 (fr) * 1991-02-08 1992-08-12 Becton, Dickinson and Company Dispositif et méthode pour renouveler les électrodes en cours d'ionophorése
US5169384A (en) * 1991-08-16 1992-12-08 Bosniak Stephen L Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue
WO1994005361A1 (fr) * 1992-08-28 1994-03-17 Cortrak Medical, Inc. Appareil a matrice polymere d'administration de medicament et procede
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 8416, Derwent World Patents Index; Class B07, AN 84-098813, XP002004807 *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033598B2 (en) * 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
GB2323791B (en) * 1997-04-01 1999-09-01 Johann Zimmermann Electromagnetic pen
GB2323791A (en) * 1997-04-01 1998-10-07 Johann Zimmermann Electromagnetic pen for skin treatment
US7799337B2 (en) * 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
EP1011698A4 (fr) * 1997-09-09 2004-05-12 Univ Western Australia Supplement osseux chimique
EP1011698A1 (fr) * 1997-09-09 2000-06-28 The University Of Western Australia Supplement osseux chimique
US9051363B2 (en) 1997-12-02 2015-06-09 Janssen Sciences Ireland Uc Humanized antibodies that recognize beta amyloid peptide
US8642044B2 (en) 1997-12-02 2014-02-04 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8034339B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8535673B2 (en) 1997-12-02 2013-09-17 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8034348B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP2002511385A (ja) * 1997-12-03 2002-04-16 ニューララブ リミテッド アルツハイマー病におけるβ−アミロイド関連変化を抑制する方法
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7252655B2 (en) 1999-05-25 2007-08-07 Iomed, Inc. Ocular iontophoretic apparatus handle
US7481781B2 (en) 2000-11-17 2009-01-27 Gendel Limited Ultrasound therapy
GB2374018A (en) * 2000-11-17 2002-10-09 Gendel Ltd Ultrasound therapy
GB2374018B (en) * 2000-11-17 2003-11-19 Gendel Ltd Ultrasound therapy
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6821274B2 (en) 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
US8202845B2 (en) 2002-04-18 2012-06-19 Acuity Pharmaceuticals, Inc. Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification
WO2003087368A3 (fr) * 2002-04-18 2004-04-29 Lynkeus Bio Tech Gmbh Moyens et procedes pour la modulation specifique de genes cibles dans le snc et l'oeil, et procedes pour leur identification
US9150863B2 (en) 2002-07-24 2015-10-06 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiogenesis
US8541384B2 (en) 2002-07-24 2013-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiogenesis
US8546345B2 (en) 2002-07-24 2013-10-01 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiogenesis
US8946403B2 (en) 2002-07-24 2015-02-03 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiogenesis
ES2267333A1 (es) * 2004-01-27 2007-03-01 Universidad De Sevilla Dispositivo para la administracion de sustancias, estimulacion y registro "daser".
US8954149B2 (en) 2004-02-20 2015-02-10 Brainsgate Ltd. External stimulation of the SPG
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9644025B2 (en) 2007-10-17 2017-05-09 Wyeth Llc Immunotherapy regimes dependent on ApoE status
US9398894B2 (en) 2007-12-21 2016-07-26 Carticept Medical, Inc. Removable cassette for articular injection system
US9067015B2 (en) 2007-12-21 2015-06-30 Carticept Medical, Inc. System for injecting fluids in a subject
US9044542B2 (en) 2007-12-21 2015-06-02 Carticept Medical, Inc. Imaging-guided anesthesia injection systems and methods
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8470792B2 (en) 2008-12-04 2013-06-25 Opko Pharmaceuticals, Llc. Compositions and methods for selective inhibition of VEGF
US8267851B1 (en) 2009-06-16 2012-09-18 James M Kroll Method and apparatus for electrically generating signal for inducing lucid dreaming
WO2013157937A1 (fr) * 2012-04-16 2013-10-24 Lerner Eduard N Dispositif d'administration intercérébrale améliorée de multiples substances biologiquement actives
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10512771B2 (en) 2013-11-10 2019-12-24 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator

Similar Documents

Publication Publication Date Title
US20020123678A1 (en) Device for enhanced delivery of biologically active substances and compounds in an organism
WO1997018855A1 (fr) Dispositif pour ameliorer l'administration a l'organisme de substances et de composes biologiquement actifs
US7033598B2 (en) Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US8634907B2 (en) Intraocular iontophoretic device and associated methods
EP1807149B1 (fr) Dispositifs de liberation prolongee in vivo d'un agent actif
US8480638B2 (en) Intraocular iontophoretic device and associated methods
US9192512B2 (en) Device for delivering medicines by transpalpebral electrophoresis
US20200085618A1 (en) Intrascleral drug delivery device and associated methods
US7084116B2 (en) Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators
US20070260171A1 (en) Intraocular iontophoretic device and associated methods
US20080027371A1 (en) Method and device for minimally invasive site specific ocular drug delivery
PT100323B (pt) Dispositivo para a reducao das sensacoes durante a administracao iontoforetica de um agente terapeutico
US20090143752A1 (en) Passive intraocular drug delivery devices and associated methods
US8755880B2 (en) Intraocular iontophoretic device and associated methods
JPH09503136A (ja) イオン導入ドラッグデリバリーシステム及び方法
WO2007050645A2 (fr) Dispositif iontophoretique intraoculaire, et procedes associes
EP0869829A1 (fr) Dispositif pour ameliorer l'administration a l'organisme de substances et de composes biologiquement actifs
MXPA98004007A (en) Device for increasing the release of biologically active substances and compounds in an organi
Dehghan et al. Advances in iontophoresis for drug delivery
RU2157257C1 (ru) Способ лечения заболеваний заднего отрезка глаза человека методом эндоназального электрофореза и установка для его осуществления
Gazelius Iontophoresis-theory
Vranić Iontophoresis: fundamentals, developments and application
Dwivedi Nasya Karma-A Unique Ayurveda Therapy
Lebedev et al. Transcranial Electrostimulation of the Brain Endophrinergic System As an Example of the Uninvasive Functional Electrostimulation of the Brain Homeostatic Mechanisms: Activation of Tissue Repair
US20180117300A1 (en) Direct current applicator for therapeutic use, with a plurality of sheet-like structures

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96199358.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2238055

Country of ref document: CA

Ref document number: 2238055

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09077123

Country of ref document: US

Ref document number: PA/a/1998/004007

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1997 519384

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996939840

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996939840

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996939840

Country of ref document: EP